A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01806064 |
|
Recruitment Status :
Active, not recruiting
First Posted : March 7, 2013
Last Update Posted : October 6, 2017
|
Sponsor:
Tracon Pharmaceuticals Inc.
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2017 |
| Estimated Study Completion Date : | June 2018 |